The phrase "approved risk" is correct and usable in written English.
It can be used in contexts related to finance, insurance, or project management where a risk has been evaluated and accepted by relevant authorities.
Example: "The project can proceed as planned since we have identified and documented the approved risk associated with the new technology."
Alternatives: "accepted risk" or "validated risk".
Theresa May's pledge to stand down if her Brexit deal is approved risks making "an already bad project even worse", Nicola Sturgeon has claimed.
We compared characteristics of clinical trials and results on safety and effectiveness reported in FDA premarket approval documents for recently approved high risk cardiovascular devices (such as coronary stents and implantable cardioverter defibrillators) with the trial characteristics and results reported in journal publications.
The committee subsequently approved a risk profile for decaBDE and plans to draft a risk management evaluation.
The MF Global board, he said, approved the risk limits for the trades, which were set on a country-by-country basis.
Because waivers are notoriously time consuming and hard to get, an applicant would typically wait months abroad for a waiver to be approved and risk being stranded from his or her family for years if it is not approved.
Observed-to-expected outcome ratios were reported using approved multivariable risk models for 30-day operative mortality and major morbidity.Of 2,676 cardiac surgeons, 668 (25.0%) operated at multiple centers.
Before any infrastructure project that size is approved, a risk assessment needs to be done.
Objective To investigate characteristics of clinical trials and results on safety and effectiveness reported in US Food and Drug Administration FDAA) documents for recently approved high risk cardiovascular devices compared with the characteristics and results reported in peer reviewed publications.
Based on clinical trial data, tamoxifen was approved for risk reduction by the US Food and Drug Administration FDAA) in 1998, and it has been endorsed for this purpose in specific categories of women by the American Society of Clinical Oncology Clinical Practice Guidelines committee [ 2, 71, 72].
A previous analysis of 151 applications for new molecular entity that received a complete response letter from 2000 to 2012 found that applications with efficacy deficiencies were more likely never to be approved (relative risk 2.24 (95% confidence interval 1.50 to 3.34), by our calculation).
